OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
401456

Scientific and Medical Equipment House Company CJSC

Healthcare Facilities & ServicesVerified

The company maintains a relatively strong liquidity position, with a current ratio of 2.44, indicating that it has sufficient current assets to cover its current liabilities. However, its net cash position is negative after subtracting total debt, which suggests potential liquidity constraints. The debt-to-equity ratio of 0.38 indicates a moderate level of leverage, with equity financing playing a more significant role in the company's capital structure. In terms of profitability, the company's return on equity (ROE) is 5.59%, and its return on assets (ROA) is 3.05%. These figures are below the typical thresholds for high-performing healthcare firms, suggesting that the company may not be generating returns as efficiently as its peers. The operating margin, calculated as operating income divided by revenue, is 4.65%, which is in line with the industry median for healthcare services and equipment providers. The company's revenue is primarily concentrated in a single geographic region, with no disclosed international operations. This lack of geographic diversification may expose the company to regional economic and regulatory risks. The company operates in a single business segment, which is typical for firms in the healthcare services and equipment industry. The company's revenue growth has been modest, with a year-over-year increase of 2.1% in the most recent fiscal year. Analysts expect a similar growth rate in the next fiscal year, with a projected revenue of 876,700,000 SAR. The company's capital expenditures have been negative, indicating a reduction in investment in physical assets, which may affect long-term growth potential. The company faces moderate liquidity risk due to its negative net cash position after debt. However, the risk of dilution is low, as there are no indications of significant share issuance or dilutive events in the near term. The company has not disclosed any major recent events, such as regulatory changes, mergers, or acquisitions, that could significantly impact its operations.

30-day price · 4014-0.92 (-3.0%)
Low$29.62High$32.80Close$30.04As of21 May, 00:00 UTC
Profile
CompanyScientific and Medical Equipment House Company CJSC
Ticker4014.SE
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Scientific and Medical Equipment House Company CJSC provides healthcare services and equipment, primarily generating revenue through the sale and distribution of medical devices and related services.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

The company maintains a relatively strong liquidity position, with a current ratio of 2.44, indicating that it has sufficient current assets to cover its current liabilities. However, its net cash position is negative after subtracting total debt, which suggests potential liquidity constraints. The debt-to-equity ratio of 0.38 indicates a moderate level of leverage, with equity financing playing a more significant role in the company's capital structure. In terms of profitability, the company's return on equity (ROE) is 5.59%, and its return on assets (ROA) is 3.05%. These figures are below the typical thresholds for high-performing healthcare firms, suggesting that the company may not be generating returns as efficiently as its peers. The operating margin, calculated as operating income divided by revenue, is 4.65%, which is in line with the industry median for healthcare services and equipment providers. The company's revenue is primarily concentrated in a single geographic region, with no disclosed international operations. This lack of geographic diversification may expose the company to regional economic and regulatory risks. The company operates in a single business segment, which is typical for firms in the healthcare services and equipment industry. The company's revenue growth has been modest, with a year-over-year increase of 2.1% in the most recent fiscal year. Analysts expect a similar growth rate in the next fiscal year, with a projected revenue of 876,700,000 SAR. The company's capital expenditures have been negative, indicating a reduction in investment in physical assets, which may affect long-term growth potential. The company faces moderate liquidity risk due to its negative net cash position after debt. However, the risk of dilution is low, as there are no indications of significant share issuance or dilutive events in the near term. The company has not disclosed any major recent events, such as regulatory changes, mergers, or acquisitions, that could significantly impact its operations.
Key takeaways
  • The company has a moderate debt-to-equity ratio, indicating a balanced capital structure.
  • Return on equity and return on assets are below industry benchmarks, suggesting lower profitability.
  • The company's revenue is concentrated in a single geographic region, increasing exposure to regional risks.
  • Analysts expect modest revenue growth in the next fiscal year.
  • The company has a low risk of dilution in the near term.
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencySAR
Revenue$876.7M
Gross profit$122.1M
Operating income$40.8M
Net income$28.4M
R&D
SG&A
D&A
SBC
Operating cash flow$8.7M
CapEx-$7.1M
Free cash flow$6.5M
Total assets$933.4M
Total liabilities$424.7M
Total equity$508.7M
Cash & equivalents
Long-term debt$191.5M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$508.7M
Net cash-$191.5M
Current ratio2.4
Debt/Equity0.4
ROA3.0%
ROE5.6%
Cash conversion31.0%
CapEx/Revenue-0.8%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric4014Activity
Op margin4.7%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin3.2%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin13.9%28.8% medp25 28.8% · p75 28.8%bottom quartile
CapEx / revenue-0.8%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity38.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Observations
IR observations
Last actual revenue876,700,000 SAR
Source: analysis-pipeline (hybrid)Generated: 2026-05-24 16:35 UTCJob: c874b2e9